Editorials from
Pharmacotherapy
Place of Dabigatran in Contemporary Pharmacotherapy
John G. Gums, Pharm.D., FCCP
(Pharmacotherapy 2011;31(4):335-337)
Payment for Clinical Pharmacy Services Revisited
JoAnn Stubbings, M.H.C.A., Edith Nutescu, Pharm.D., FCCP, Sandra F. Durley, Pharm.D., and
Jerry L. Bauman, Pharm.D., FCCP, FACC
(Pharmacotherapy 2011;31(1):1-8)
Pharmacists and Health Reform: Go for It!
Helene Levens Lipton, Ph.D.
(Pharmacotherapy 2010;30(10):967-972)
Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers
Daniel E. Hilleman, Pharm.D., FCCP, and Aryan N. Mooss, M.D.
(Pharmacotherapy 2010;30(9):867-871)
Designing Quality Health Services Research: Why Comparative Effectiveness Studies Are Needed and Why Pharmacists Should Be Involved
Barry L. Carter, Pharm.D., FCCP, FAHA
(Pharmacotherapy 2010;30(8):751-757)
Precision versus Approximation: The Trade Off in Assessing Kidney Function and Drug Dosing
Michelle M. Richardson, Pharm.D., FCCP
(Pharmacotherapy 2010;30(8):758-761)
Clopidogrel and Proton Pump Inhibitors: Between a Rock and a Hard Place
Kathryn Momary, Pharm.D., and Larisa H. Cavallari, Pharm.D.
(Pharmacotherapy 2010;30(8):762-765)
Opioid Harm Reduction Strategies: Focus on Expanded Access to Intranasal Naloxone
Daniel P. Wermeling, Pharm.D., FCCP, FASHP
(Pharmacotherapy 2010;30(7):627-631)
Improving Adherence in the Community and Clinic Pharmacy Settings: An Emerging
Opportunity
Daniel R. Touchette, Pharm.D., M.A.
(Pharmacotherapy 2010;30(5):425-427)
Changes in the USP Heparin Monograph and Implications for Clinicians
Maureen A. Smythe, Pharm.D., FCCP, Edith A. Nutescu, Pharm.D., FCCP, and Ann K. Wittkowsky, Pharm.D., FASHP, FCCP
(Pharmacotherapy 2010;30(5):428–431)
Anticoagulation Management Services: Entering a New Era
Edith A. Nutescu, Pharm.D., FCCP
(Pharmacotherapy 2010;30(4):327–329)
You Don’t Know What You’ve Got Till It’s Gone
John G. Gums, Pharm.D., FCCP
(Pharmacotherapy 2010;30(3):221–223)
Monitoring Vitamin D Concentrations in Patients with Osteoporosis: A Clinical Perspective
(Pharmacotherapy 2010;30(3):224-227)
Sunny A. Linnebur, Pharm.D., FCCP, FASCP,| Joseph P. Vande Griend, Pharm.D., and| Jeffrey I. Wallace, M.D., M.P.H.
An Aspirin a Day: Are We Barking Up the Wrong Willow Tree?
Mori J. Krantz, M.D., Jeffrey S. Berger, M.D., and William R. Hiatt, M.D.
(Pharmacotherapy 2010;30(2):115-118)
Clopidogrel versus Prasugrel: Times Are Changing, but Not for Everyone
Paul P. Dobesh, Pharm.D., FCCP
(Pharmacotherapy 2009;29(12):1393–1396)
Predicting the Supply of Pharmacy Residencies
John E. Murphy, Pharm.D., FCCP
Pharmacotherapy 2009;29(9):1014-1016)
Accreditation: We Want Standards, Not Standardization
Mary Anne Koda-Kimble, Pharm.D., and Marilyn K. Speedie, Ph.D.
Pharmacotherapy 2009;29(5):491-494)
A Ghost in the Machine
Richard T. Scheife
(Pharmacotherapy 2009;29(4):363-364)
Warfarin and Pharmacogenomic Testing: What Would Pascal Do?
J. Russell Teagarden
(Pharmacotherapy 2009;29(3):245-247)
Pharm.D.-Only Investigators Are Critical to the Profession: Let's Preserve the Fellowship as an Equally Important Way to Prepare Future Clinical Pharmaceutical Scientists: Or the Case Against the “All-Ph.D.”
Jerry L. Bauman, William E. Evans
(Pharmacotherapy 2009;29(2):129-133)
Training Clinical Pharmaceutical Scientists in Today's Highly Competitive Times: It's Time to Commit to Change
Robert A. Blouin, Gary M. Pollack
(Pharmacotherapy 2009;29(2):134-137)
Nighttime Blood Pressure Is the Blood Pressure
Michael E. Ernst
(Pharmacotherapy 2009;29(1):3-6)
Modulation of Clopidogrel Pharmacodynamic Response
Federico M. Goodsaid
(Pharmacotherapy 2008;28(12):1423-1424)
Preventing Thiazide-Induced Hyperglycemia: Opportunities for Clinical Pharmacists
Barry L. Carter
(Pharmacotherapy 2008;28(12):1425-1428)
Scared to Death
Michael R. Ujhelyi
(Pharmacotherapy 2008;28(11):1311)
Warfarin: An Old Drug but Still Interesting
Julie A. Johnson
(Pharmacotherapy 2008;28(9):1081-1083)
What is a Pharmacotherapy Residency? Benefits of a 24-Month Program
Jean Nappi, Krystal Haase, Anthony Kessels, Jodie Fink
(Pharmacotherapy 2008;28(7):819-820)
Genetic Testing for Warfarin Dosing? Not Yet Ready for Prime Time
Henry I. Bussey, Ann K. Wittkowsky, Elaine M. Hylek, Marie B. Walker
(Pharmacotherapy 2008;28(2):141-143)
Putting New Disease-Modifying Antirheumatic Drugs into Perspective
Joseph J. Saseen
(Pharmacotherapy 2007;27(12):1609-1610)
Changing the Structure of Pharmaceutical Education to Require Doctor of Pharmacy and Postgraduate Residency Education and Training
William A. Miller
(Pharmacotherapy 2006;26(5):587-593)
Clinical Maturity in Pharmacy
Max D. Ray
(Pharmacotherapy 2006;26(5):594-596)
Against the Wind
Donald E. Letendre
(Pharmacotherapy 2006;26(5):597-600)
Higher, Faster, Farther
Richard T. Scheife, Stephen E. Cavanaugh
(Pharmacotherapy 2006;26(2):151-153)
Fluoroquinolone-Associated Dysglycemias: A Tale of Two Toxicities
Robert C. Owens Jr
(Pharmacotherapy 2005;25(10):1291-1295)
Blood, Sweat, and Tears: Wasted by Medicare’s Missed Opportunity
Henry I. Bussey
(Pharmacotherapy 2004;24(12):1655-1658)
Pharmacovigilance in the 21st Century: New Systematic Tools for an Old Problem
Ana Szarfman, Joseph M. Tonning, P. Murali Doraiswamy
(Pharmacotherapy 2004;24(9):1099-1104)
Pharmacotherapy
Goes Online
Richard T. Scheife, Steve Cavanaugh
(Pharmacotherapy 2004;24(7):821-823)
Autism and Measles-Mumps-Rubella (MMR) Vaccination: A Challenge for Pharmacoepidemiology
David C. G. Skegg
(Pharmacotherapy 2003;23(12):1521-1523)
Pharmacy Education: Back to the Basics?
William D. Figg, Michael C. Cox
(Pharmacotherapy 2003;23(11):1381-1390)
The Diabetes Epidemic: Can We Stop the Spread?
Stuart T. Haines
(Pharmacotherapy 2003;23(10):1227-1231)
Osmolality and Osmolarity: Narrowing the Terminology Gap
Brian L. Erstad
(Pharmacotherapy 2003;23(9):1085-1086)
The United States Civilian Smallpox Vaccination Program: Have We Thought Through the Whole Issue?
Mike D. Schwartz
(Pharmacotherapy 2003;23(3):271-273)
Clinical Monitoring of Direct Thrombin Inhibitors Using the Ecarin Clotting Time
Simon de Denus, Sarah A. Spinler
(Pharmacotherapy 2002;22(4):433-435)
Pharmacoeconomic Studies of Asthma Controller Drugs: Marketing Gimmick or Icing on the Cake?
Leslie Hendeles, Richard Segal
(Pharmacotherapy 2002;22(2):131-133)